Alphabet’s Isomorphic, an AI biotech startup, is making headlines with major pharmaceutical partnerships. Let’s dive into this exciting development in the AI and biotech world.
Isomorphic’s Big Pharma Breakthrough
Isomorphic has just inked deals with giants Eli Lilly and Novartis. The terms? An impressive $83 million upfront and potential milestone payments up to $2.9 billion. That’s huge!
Leveraging AlphaFold for Drug Discovery
Here’s where it gets interesting: Isomorphic uses Google DeepMind’s AlphaFold model. This is all about using AI to speed up drug discovery, a game-changer in pharmaceuticals.
Rapid Rise in AI Biotech
Since its start in November 2021, Isomorphic has been on a fast track. In less than a year, they’ve positioned themselves as key players in AI biotech.
Leadership and Growth
- At the Helm: Demis Hassabis, CEO of Google DeepMind, is leading the charge. His expertise in AI is steering Isomorphic towards success.
- Team and Locations: About 90 employees are fueling Isomorphic’s growth, based in London and Lausanne, Switzerland.
The Bottom Line
Isomorphic’s recent partnerships mark a significant milestone in AI-driven drug discovery. With its advanced use of AI and rapid growth, the company is set to revolutionize how we approach pharmaceuticals. Keep an eye on Isomorphic – they’re pushing boundaries in the exciting convergence of AI and biotech! 🚀💊🤖